Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14200369 | 0.83 | ALDH1A1 (0.57) | KMT2AALDH1A1NPSR1NPC1POLB | |
| SCHEMBL11715175 | 0.78 | CYP2C19 (0.59) | KMT2AALDH1A1CYP2C19HIF1AMEN1 | |
| SCHEMBL4098442 | 0.77 | CYP2C19 (0.69) | KMT2AALDH1A1HTTCYP2C19HIF1A | |
| SCHEMBL408175 | 0.73 | CYP2C19 (0.53) | KMT2AALDH1A1CYP2C19HIF1AMEN1 | |
| SCHEMBL1537402 | 0.73 | CYP2C19 (0.53) | KMT2AALDH1A1POLBCYP2C19HIF1A | |
| SCHEMBL362442 | 0.73 | KMT2A (0.55) | KMT2AALDH1A1HTTCYP2C19HIF1A | |
| SCHEMBL9474959 | 0.73 | CYP2C19 (0.53) | KMT2AALDH1A1HTTCYP2C19HIF1A | |
| SCHEMBL27617111 | 0.73 | ALDH1A1 (0.53) | KMT2AALDH1A1NPSR1NPC1POLB | |
| SCHEMBL2345303 | 0.72 | ALDH1A1 (1.00) | KMT2AALDH1A1NPSR1NPC1POLB | |
| SCHEMBL2781437 | 0.72 | ALDH1A1 (0.63) | KMT2AALDH1A1NPSR1NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192220-A1 | TREATMENT FOR SOLID TUMORS | ORE PHARMACEUTICALS INC. (US) | 2009-07-30 | — | — | US | claimed |
| WO-2009067397-A2 | TREATMENT FOR SOLID TUMORS | ORE PHARMACEUTICALS INC. (US) | 2009-05-28 | — | — | WO | claimed |
| US-20090192220-A1 | TREATMENT FOR SOLID TUMORS | ORE PHARMACEUTICALS INC. (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192220-A1 | TREATMENT FOR SOLID TUMORS | ACAT2, ACAT1, APRT | KMT2A 132/4885ALDH1A1 188/4885NPSR1 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.